Close
Close

Suvizumab (CAT#: TAB-068)

Datasheet
DESCRIPTION CATALOG # SIZE PRICE
Anti-HIV-1 Recombinant Antibody TAB-068 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant monoclonal antibody to HIV-1. Itolizumab (INN, trade name Alzumab) is a 'first in class' humanized IgG1 monoclonal antibody. It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation. A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo. Biocon has received marketing authorization for the drug from the Drugs Controller General of India (DCGI).
  • Target
  • HIV-1
  • Type
  • IgG1 - kappa
  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Species Reactivity
  • HIV-1
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in WB, IF, IP, Neut, FuncS, ELISA, FC and most other immunological methods.
  • CAS
  • 1116433-11-4
  • Specific Activity
  • Tested positive against native HIV-1 antigen.
  • Purity
  • >95.0% as determined by analysis by RP-HPLC.
  • Size
  • 1mg
  • Storage
  • Store at -20°C. Avoid multiple freeze/thaw cycles.

BACKGROUND

  • Introduction
  • This antibody is an antiviral and immunomodulator.
  • Antigen Description
  • HIV is a highly variable virus which mutates very readily. This means there are many different strains of HIV, even within the body of a single infected person. The strains of HIV1 can be classified into three groups : the "major" group M, the "outlier" group O and the "new" group N. These three groups may represent three separate introductions of simian immunodeficiency virus into humans. Group O appears to be restricted to West-Central Africa and group N, discovered in 1998 in Cameroon, is extremely rare. More than 90% of HIV1 infections belong to HIV1 group M.
  • Keywords
  • HIV 1; HTLV3; Human Immunodeficiency Virus 1

Customer reviews and Q&As    

Related Products
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us